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Abstract
Background: The efficacy of current anticancer treatments is far from satisfactory and many patients still die of their disease.
A general agreement exists on the urgency of developing molecularly targeted therapies, although their implementation in
the clinical setting is in its infancy. In fact, despite the wealth of preclinical studies addressing these issues, the difficulty of
testing each targeted therapy hypothesis in the clinical arena represents an intrinsic obstacle. As a consequence, we are
witnessing a paradoxical situation where most hypotheses about the molecular and cellular biology of cancer remain
clinically untested and therefore do not translate into a therapeutic benefit for patients.
Objective: To present a computational method aimed to comprehensively exploit the scientific knowledge in order to
foster the development of personalized cancer treatment by matching the patient’s molecular profile with the available
evidence on targeted therapy.
Methods: To this aim we focused on melanoma, an increasingly diagnosed malignancy for which the need for novel
therapeutic approaches is paradigmatic since no effective treatment is available in the advanced setting. Relevant data were
manually extracted from peer-reviewed full-text original articles describing any type of anti-melanoma targeted therapy
tested in any type of experimental or clinical model. To this purpose, Medline, Embase, Cancerlit and the Cochrane
databases were searched.
Results and Conclusions: We created a manually annotated database (Targeted Therapy Database, TTD) where the relevant
data are gathered in a formal representation that can be computationally analyzed. Dedicated algorithms were set up for
the identification of the prevalent therapeutic hypotheses based on the available evidence and for ranking treatments
based on the molecular profile of individual patients. In this essay we describe the principles and computational algorithms
of an original method developed to fully exploit the available knowledge on cancer biology with the ultimate goal of
fruitfully driving both preclinical and clinical research on anticancer targeted therapy. In the light of its theoretical nature,
the prediction performance of this model must be validated before it can be implemented in the clinical setting.
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Introduction
Targeted Therapy in Cancer Medicine
Cancer represents the third leading cause of death worldwide
and the second in Western countries [1,2]. Early diagnosis
continues to offer the best chance of cure for most tumor types.
The efficacy of currently available anticancer treatments are far
from satisfactory in the advanced/metastatic setting where most
patients succumb to their disease. General agreement exists
regarding the urgency of developing molecularly targeted
therapies, their implementation in the clinical setting being in its
infancy [3,4,5,6,7,8].
The term ‘‘targeted therapy’’ includes all those approaches that
aim to tailor the therapy to the patient (or cohort of patients) based
on specific molecular features of the disease- and/or patient
[3,7,9,10,11,12,13,14]. The ultimate goal is obviously to maximize
the therapeutic efficacy while minimizing the toxicity, that is,
increasing the ‘‘therapeutic index’’. In cancer medicine, tumor-
specific molecular derangements (e.g., gene mutation or protein
overactivation), are the ideal targets for therapeutic strategies
aimed to kill malignant cells while sparing normal cells.
Furthermore, patient-specific molecular features such as polymor-
phisms of detoxifying enzymes can affect the metabolism of
anticancer drugs and thus can play a role in both efficacy and
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targeted therapy includes not only the development and clinical
implementation of ‘‘smart’’ drugs (i.e., agents that target tumor-
specific molecular derangements), but also the identification of the
patient molecular profile that maximizes the therapeutic index of
‘‘conventional’’ chemotherapeutics.
Therefore, the two mainstreams of research in the field of
targeted anticancer therapy can be summarized as follows:
A) to develop novel therapeutic agents based on the molecular
‘‘Achilles’ heel(s)’’ of malignant cells, which usually implies
the selection of patients bearing a cancer that harbors that
specific molecular derangement;
B) to identify biomarker(s) predictive of tumor responsiveness
based on the molecular characteristics of both the patient
and the tumor; this approach, ultimately, would lead to
administer conventional and/or targeted drugs only to
patients with the greatest likelihood of responding and the
least likelihood of suffering from side effects.
Research on anticancer targeted therapy has made several
advances; a number of ‘‘smart’’ approaches have now reached the
clinical phase of experimentation and some of them have been
approved for the routine treatment of patients affected by specific
types of cancer [5,8,15,16,17,18,19,20,21,22]. Nevertheless, there
is general agreement that most work is still to be done before we
can state that targeted therapy is the standard of care for cancer.
In this regard, the most important hurdles appear the following: 1)
elucidation of the molecular pathways governing disease develop-
ment and progression has provided investigators with numerous
potential new therapeutic targets, but has at the same time
exponentially increased the number of variables that must be
taken into account when designing new drugs and trials; 2) the
ever growing amount of information generated by the scientific
community stands in striking contrast to the parallel lack of
publicly available bioinformatic tools capable of integrating data
and knowledge in a rationally organized, biologically informative
and therapeutically oriented manner, which would maximize the
likelihood of finding the shortest path to effective cancer
treatments; 3) therapy personalization requires the study of
molecular profiles on a single-patient basis, which requires the
availability of huge computable biological databanks; a formidable
corollary issue is that data sharing implies the compatibility of
different technological platforms used around the world by
different investigators (as exemplified by the CaBig project,
https://cabig.nci.nih.gov); 4) the costs for the development and
the production of ‘‘smart’’ drugs may pose problems of expenses
that cannot be sustained by either public or private research
institutions or even by national health care systems.
Overall, despite the wealth of preclinical studies addressing
the issue of targeted anticancer therapy, the complexity of
testing each preclinical hypothesis in the clinical arena
represents an intrinsic obstacle. As a consequence, the gap is
widening between the pace of discovery in the field of cancer
biology and the improvements in therapeutic benefit for
patients. In particular, the scientific community has only
recently acknowledged that the lack of tools for the systematic
and therapy-oriented collection of the biomedical data may
ultimately cause an enormous and paradoxically unethical waste
of information [23,24,25,26,27,28,29,30,31,32].
The creation of an open-access repository for the storage and
the analysis of data on targeted therapy is a relatively feasible step
towards the full exploitation of the information produced by the
scientific community. Although some attempts have been made in
this direction [33,34,35,36,37,38,39], no disease-specific project
exists to systematically collect and comprehensively exploit
scientific data for the therapeutic management of patients.
The objective of the present project is to create a manually
annotated database where the relevant data are gathered in a
formal representation that can be computationally analyzed for
the identification of therapeutic hypotheses based on the available
evidence and for ranking treatments based on the molecular
profile of single patients.
To this aim we focused on melanoma, an increasingly
diagnosed malignancy for which there is an urgent need to
develop novel therapeutic approaches since no effective treatment
is available, especially in the advanced setting.
The case of melanoma
Although cutaneous malignant melanoma is the least common
form of skin cancer, it accounts for 75% of skin cancer deaths
[2,40,41,42,43]. During most of the twentieth century, the
incidence of melanoma in populations of European origin rose
faster than any other solid cancer, barring lung cancer. An
estimated 160,000 new cases and 41,000 deaths were reported
worldwide in 2002. In the United States, the American Cancer
Society reported approximately 60,000 new cases of melanoma
(with an estimated lifetime risk of 1 in 49 for men and 1 in 73 for
women), leading to an expected 8,110 deaths in 2007. In
comparison, the incidence in 2001 was approximately 47,700
new cases. This underscores that melanoma is an important and
growing public health concern.
The therapeutic management of cutaneous melanoma is one of
the most challenging issues for oncologists [40,41,42]. Because
melanoma is among the solid malignancies most refractory to
medical therapy, early diagnosis coupled with surgical removal of
the primary tumor is virtually the only curative approach currently
available. For metastatic melanoma, no conventional or molecu-
larly targeted drug is better than dacarbazine (DTIC); however,
there is no convincing evidence that DTIC is better than best
supportive care [44,45,46].
In patients with high-risk melanoma, ie, with American Joint
Committee on Cancer (AJCC) TNM stage II (T2-4 N0 M0) and
III (Tany N+ M0) disease the rate of disease recurrence ranges
between 20% to 60%, with 5-year overall survival (OS) varying
between 45% and 70% [47]. The only agent currently approved
treatment for such patients after apparently radical surgery (ie,
adjuvant setting) is interferon (IFN) alpha [48]: according to the
most recent meta-analysis published on this subject, the use of
IFN-alpha reduces the risk of death by about 10% [49].
Overall, it is clear the urgency of accelerating the pace at which
novel, effective therapeutic options can be offered to patients
affected with melanoma.
From a translational perspective, one way of maximizing the
practical usefulness of the available scientific evidence would be to
share the knowledge and organize it in a computationally oriented
fashion: ultimately, this would allow to comprehensively utilize
both clinical and preclinical information on targeted therapy for
the therapeutic management of patients.
In 2007 we have started an initiative in this direction by
launching the Melanoma Molecular Map Project (MMMP,
http://www.mmmp.org), an open-access website dedicated to
the systematic collection of scientific information on melanoma
biology and treatment [50]. The MMMP website, which presently
collects more than 4,000 records distributed in seven intercon-
nected databases, currently ranks first as ‘‘melanoma database’’ in
the Google search engine.
Targeted Therapy Database
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MMMP database called Targeted Therapy Database (TTD),
which specifically focuses on the available scientific information
that can be exploited to promote the development of personalized
treatments for patients affected with melanoma.
Methods
The Targeted Therapy Database
The Targeted Therapy Database (TTD) is a systematic
collection of the scientific knowledge regarding the development
of targeted therapy for melanoma. A copy of the database is
available as an open-access file in the MMMP website (http://
www.mmmp.org).
This database is intended to gather in a standardized and
computationally oriented fashion the published evidence on the
molecular features that have been so far investigated to develop
melanoma-specific therapies.
The TTD can be queried for the following purposes:
1) To provide both basic researchers and clinical investigators
with an unprecedented synopsis of the available scientific
literature regarding the targeted therapy of melanoma;
2) To obtain summaries of the current evidence about the
relationship between single molecules (or set of molecules)
and the efficacy (or toxicity) of a given therapeutic agent (or
set of therapeutic agents); summaries regarding the syner-
gisms between drugs (conventional and/or targeted drugs)
can also be obtained;
3) To match the patient (cancer) molecular profile with the
available scientific evidence about the targeted therapy of
melanoma, thus developing a drug ranking system for the
personalized treatment of melanoma.
As such, the information collected in the TTD will provide an
overall picture of the data produced by the scientific community
with regard to anti-melanoma targeted therapy, which are
currently scattered in thousands of individual articles published
in hundreds of journals often not open-access. Even more
importantly, the computational analysis of the TTD data may
prove useful to promote both the preclinical and clinical
development of patient-tailored therapy based on the comprehen-
sive (instead of piecewise) use of the available evidence.
Data collection
The sources of the information input in the TTD are the
PubMed, Medline, Embase, Cancerlit and Cochrane databases.
Our literature search is aimed to identify scientific evidence about
the relationship between:
A) any molecule (each in a particular state, such as mutated,
overxpressed, phosphorylated and so on) and the anti-
melanoma efficacy of a therapeutic agent being used or being
investigated for the treatment of melanoma (i.e., relationship
of sensitivity/resistance);
B) any molecule and the toxicity of any therapeutic agent being
used or being investigated for the treatment of melanoma
(i.e., relationship of toxicity);
C) any molecule that - after modulation of its functional state by
a ‘‘modifier’’ (e.g., inhibition by a drug) - can increase (or
decrease) the efficacy a therapeutic agent being used or being
investigated for the treatment of melanoma (i.e., relationship
of synergism/antagonism).
Only original full-length articles are taken into consideration, so
to guarantee that the data collected in the TTD are supported by
research works whose methods, results and conclusions are fully
reported in a manuscript that has passed through a standard peer-
review process.
At the time of writing, over 1,200 records (ie, database rows)
have been created, which cover more than 50% of the relevant
literature published between January 2000 and January 2010,
while for previous years the coverage is currently less than 50%.
Our commitment is to complete the literature search back to
January 1990 over the next 12 months.
Our search is systematic, that is, no key word other than
‘‘melanoma’’ is utilized, the only restriction being the English
language. Accordingly, any type of study (i.e., preclinical/clinical,
human/animal, in vitro/in vivo) regarding any type of melanoma
(i.e., cutaneous, mucosal, uveal) is allowed to contribute to the
content of the database.
Data organization
Information is extracted from each retrieved article according to
the following driving principle: the Authors of each article describe
their findings and virtually always come to a main conclusion,
whether ‘‘positive’’ (e.g., a molecule in a specific state can favor
tumor response to a given treatment), ‘‘negative’’ (e.g., a molecule
in a specific state can oppose tumor response) or ‘‘null’’ (e.g.,
tumor response is unaffected by a given molecule in a specific
state). In other words, each study sustains one targeted therapy
hypothesis, whether positive (the relationship between molecule
and drug is favorable for the patient), negative (unfavorable) or
null (unimportant, not influential).
Data are organized in rows and columns using a Microsoft
Excel file. Each row contains the main data representing the
targeted therapy hypothesis made by the Authors of a given
article. Each column contains one type of data according to a
standardized format.
The following 15 columns compose the database:
1) ID: this is a unique number identifying each record (that is,
each row of the database).
2) Source: this indicates the tissue/cell type where the molecule
under investigation (see next column) is expressed/present.
For instance: somatic mutations of BRAF are investigated in
melanoma specimens, polymorphisms of genes involved in
drug metabolism can be studied in any patient’s nucleated
cell, and expression of cytokine receptors can be assessed in
immune cells.
3) Molecule: this is the name of the molecule under investigation
as a tumor-specific target, or as a biomarker of sensitivity/
toxicity of melanoma/patient to therapeutic agents. The
molecule’s name is generally that reported by the Authors of
the corresponding article.
4) Alias (molecule): since molecules often have multiple names,
aliases are reported in this column in order to clarify
molecules’ identity. Aliases are chosen on the basis of
international databases such as HUGO (http://www.
genenames.org) and Uniprot (http://www.uniprot.org).
5) State (molecule): this refers to the condition (e.g., mutated,
overexpressed, phosphorylated) under which the molecule
exerts the biological activity related to the targeted therapy
hypothesis reported in the article. For instance, the
expression ‘‘mut V600E’’ for the protein BRAF refers to
its V600E mutation (as opposed to the wild type protein or
any other mutational status).
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laboratory method that can modulate the biological function
of a molecule of interest so to interfere with the efficacy of a
therapeutic agent. For instance, a small molecule inhibitor
can decrease the activity of a target molecule, which may
ultimately affect the efficacy of an anticancer drug; likewise,
technology based on RNA interference (e.g. small interfering
RNA) can downregulate the expression of a gene of interest
which may ultimately impact on the melanoma sensitivity to
a given treatment.
7) Alias (modifier): since modifiers often have multiple names,
aliases can be found in this column in order to facilitate their
identification.
8) Relationship: this column reports the hypothesized relation-
ship between the molecule of interest and the corresponding
treatment/drug (see ‘‘Drug’’ column). Three main types of
relationships are considered: A) Efficacy: the molecule
under investigation can be associated with either sensitivity
or resistance to a therapeutic agent; B) Synergism: the
modulation of a molecule activity by a modifier (see
‘‘Modifier’’ column) can be associated with an increased
(synergism) or decreased (antagonism) therapeutic activity of
a given drug/treatment; C) Toxicity: the molecule under
investigation can be associated with either increased or
decreased toxicity of a given drug/treatment. Of course, all
these associations can be reported to be absent. For the
purpose of prompt identification, positive (i.e. with positive
effects on anti-melanoma treatment), negative (i.e. with
adverse effects) and null associations are highlighted with
different colors (green, orange and blue, respectively).
9) Drug (therapy): this is the drug (or more generally the
treatment) whose effectiveness can be influenced (positively,
negatively or not significantly) by the molecule listed in
column ‘‘Molecule’’. The drug’s name generally is that
reported by the Authors of the corresponding article.
10) Alias (drug): since drugs often have multiple names, one alias
of the drug of interest is often reported in this column in
order to clarify its identity.
11) Model: this column reports the model used by the Authors to
generate the hypothesis. Seven different models are
considered:
1) animal, in vitro (e.g., murine melanoma cell line)
2) animal, in vivo (e.g., syngeneic murine melanoma
model)
3) human in vitro (e.g., human melanoma cell line)
4) human xenograft (e.g., human melanoma xenogeneic
model)
5) clinical study/non-randomized clinical trial
6) randomized controlled trial
7) meta-analysis of clinical trials/studies
This order is dictated by the ‘‘distance’’ of the model from
the human-in vivo condition, or - in other words - by the
level of evidence of the published data. This order will play a
key role in the ‘‘weight’’ assigned to each study, as described
in detail later on.
1) H (hypothesis): As above mentioned, each article can be
classified according to the main conclusions of its Authors
supporting a ‘‘positive’’ hypothesis (e.g., a molecule in a
specific state can favor tumor response to a given treatment),
‘‘negative’’ hypothesis (e.g., a molecule in a specific state can
oppose tumor response) or ‘‘null’’ hypothesis (e.g., tumor
response is unaffected by a given molecule in a specific
state). Following this principle, each record (row) of the
TTD is assigned a value that identifies the corresponding
hypothesis (+1, 21 or 0, respectively).
2) Cases: this is the number of cases (e.g., patients, animals, cell
lines) examined. At present, this information is only
available for clinical studies/trials (i.e., number of patients).
3) Reference: the citation of the source of information is reported.
4) Notes: additional information on the study results/features
can be found in this column in order to facilitate the
interpretation of the data reported in the previous columns.
This information can help users understand whether or not
the molecular condition described in the record applies to
their research/clinical question.
The information found in the TTD regards cutaneous
melanoma, except for drug toxicity data (which are independent
of the tumor type). If the entry relates to uveal melanoma, this is
specified at the beginning of the column ‘‘Notes’’ by the bolded
expression ‘‘Uveal melanoma’’. Therefore, should one be
interested exclusively in targeted therapy for uveal melanoma,
data must be ordered by column ‘‘Notes’’: this way the
information contained in this column is rearranged in the
alphabetical order and data on uveal melanoma will appear
towards the end of the database as a sequence of rows tagged by
the expression ‘‘Uveal melanoma’’ written in the column ‘‘Notes’’.
Likewise, information on specific subtypes of melanoma (e.g.,
acral lentiginous melanoma, mucosal melanoma) can be easily
retrieved using the same method.
Information on gene polymorphisms and drug toxicity can
derive from non-melanoma models, as specified in the ‘‘Notes’’
column in bold character.
Results
Synopsis of the evidence
As above mentioned, the goal of the TTD is to enable
investigators to find targeted therapy related information orga-
nized in a standardized and computationally oriented fashion.
Since data are collected in an Excel file, they can be ordered by
each of the 15 columns and also by any combination of three
columns is sequential order.
For instance, by sorting the database by ‘‘Molecule’’, ‘‘State’’
and ‘‘Drug’’ (in this order), one can easily obtain for each molecule
(and its state) the list of therapeutic agents whose efficacy is
influenced by that molecule (in that particular state), as shown in
Figure 1.
On the other hand, by sorting the database by ‘‘Drug’’,
‘‘Molecule’’ and ‘‘State’’ (in this order), one can easily obtain for
each therapeutic agent the list of molecules (and their state) that
can modulate its efficacy, as shown in Figure 2.
Likewise, by sorting the database by ‘‘Drug’’, ‘‘Relationship’’ and
‘‘Modifier’’ (in this order),one caneasilyobtain for each therapeutic
agent the list of compounds that can modulate its efficacy.
Obviously, many other searches can be performed by ordering
the columns on the basis of a specific interest (e.g., evidence only
from human models) or research question (e.g., ‘‘what gene
polymorphisms affect the toxicity of cisplatin ?’’).
Summary of the evidence
One aim of the TTD is to allow researchers to conveniently
summarize the available evidence on a given subject. This is an
12)
13)
14)
15)
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the problem of multiple (sometime overwhelmingly numerous)
inputs that often are not concordant (if not conflicting).
The standard way of making a quantitative review of the
available scientific knowledge is performing a meta-analysis, which
is considered the highest level of evidence in medicine, particularly
when based on randomized controlled trials [51,52,53,54,55,56].
The basic idea behind a meta-analysis is to calculate the weighted
mean of the results reported by different studies regarding a
particular subject; to this aim, the following key steps must be
taken: 1) an effect measure (e.g., odds ratio, hazard ratio, relative
risk, risk difference, mean, rate) common to all the studies must be
Figure 1. Example of evidence synopsis regarding the targeted therapy of melanoma, as obtained by searching the Targeted
Therapy Database (TTD). The available evidence on the relationship between a molecule state (BRAF mutation V600E) and its effects on different
therapeutic agents is shown. Due to space considerations, neither all columns nor all rows are displayed.
doi:10.1371/journal.pone.0011965.g001
Figure 2. Example of evidence synopsis regarding the targeted therapy of melanoma, as obtained by searching the Targeted
Therapy Database (TTD). The available evidence on the relationship between a drug (temozolomide) and the molecular determinants of its
therapeutic effect is shown. Due to space considerations, neither all columns nor all rows are displayed.
doi:10.1371/journal.pone.0011965.g002
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calculated) from each study; and then 3) the weighted mean of the
effect sizes (overall effect) can be computed. From a therapeutic
perspective, the overall effect quantifies the benefit (or the harm) of
a given treatment, and the confidence interval (CI) represents the
measure of uncertainty about its estimate (which in turn
determines the statistical significance in terms of type I error,
based on the predefined alpha level of significance).
In the light of these considerations, one can see that meta-
analysis is not appropriate for summarizing the information
contained in the TTD. In fact, the different effect measures
adopted by the Authors to describe the results obtained in different
models (ranging from animal in vitro models to randomized
clinical trials) cannot be pooled together. Moreover, even if the
effect measures were the same, different experimental models
cannot be considered equally informative and reliable: obviously,
human and in vivo models provide a higher level of evidence as
compared to animal and in vitro models (provided that each study
is equally well designed, performed and analyzed).
Therefore, the TTD cannot be exploited to calculate an overall
effect size for a given therapeutic approach, which is why it does
not record the effect sizes of the single studies.
What then is meant by ‘‘summary of the evidence’’ within the
TTD ?
As above mentioned, each study (which is represented by a row
of the database) can be envisaged as a working hypothesis about a
targeted therapy against melanoma. When more than one record
(i.e., one row of the database) exists for a given hypothesis (e.g.,
BRAF mutation V600E modulates the efficacy of small molecule
inhibitor sorafenib), we propose a score-based approach to make a
summary of the available evidence. With this method we aim to
identify the ‘‘prevalent’’ hypothesis, a process taking the following
steps (see also Figure 3):
1) As reported in column ‘‘H (hypothesis)’’, each record (i.e.,
each row of the database) is assigned one of the integer numbers
‘‘+1’’, ‘‘21’’ or ‘‘0’’, based on the fact that it represents a piece of
evidence in support of one of the three possible hypotheses (as
expressed by the Authors of the corresponding manuscript):
A) positive relationship (green color in the ‘‘Relationship’’ column):
the study supports the hypothesis that the molecule (e.g.
BRAF) in a particular state (e.g. mutation V600E) is
associated with increased efficacy of a drug, synergism
between drugs or decreased toxicity of a drug. On the
practical ground, a patient carrying this molecule (in this
specific state) would benefit from the given treatment;
B) negative relationship (orange color): the study supports the
hypothesis that the molecule can oppose the efficacy of the
drug; a patient (tumor) carrying this molecule (in this specific
state) would be refractory to the given treatment
C) null relationship (blue color) if the study supports the hypothesis
that the molecule does not change the efficacy of the drug;
knowing that a patient (tumor) carries this molecule (in this
specific state) would be uninformative in terms of respon-
siveness to the treatment.
2) As reported in the ‘‘Model’’ column, each record is also
assigned a score (model score), based on the experimental/
clinical model used to generate the targeted therapy hypothesis.
Clearly, the evidence coming from an in vitro study carried out
with murine melanoma cell lines cannot have the same ‘‘weight’’
as the evidence derived - for instance - from a study performed in a
human trial model. The closer the model to the in vivo human
condition, the higher the level of evidence and thus the greater is
the weight assigned to that study.
Within the frame of this arbitrary score, the proportion between
the weights of ‘‘adjacent’’ models is fixed: in particular, the score of
each model is twice that of the immediately precedent model. The
starting score (model: animal, in vitro) was set to 6 because this is
the smallest natural number that meets the decision rule below
described (in case a single study based on such a model supported
a given hypothesis).
The evidence score is then adjusted according to an additional
weight (size score), which is based on the number of cases (e.g.,
patients, animals, cell lines) analyzed (‘‘Cases’’ column): this way,
studies describing results obtained from larger series are assigned a
higher score.
The total evidence score (ESi) for each hypothesis i is
computed according to the following formula:
ESi~ Model score ðÞ | Size score ðÞ ,
where Size score=n/10 (n is the sample size [e.g., number of
patients enrolled] of the study under evaluation).
3) The percentage of the evidence score (score percentage,
SP) in favor of each of the three above mentioned hypotheses (i.e.,
positive, negative, null) is simply defined as the proportion between
the evidence score in favor of each hypothesis i and the sum of the
evidence score of all hypotheses:
SP~ESi=
X
ESi ðÞ
4) At this point, a decision rule must be applied to determine
whether or not a prevalent hypothesis exists: we chose 50% (0.5) of
the evidence score as the minimum value to define the prevalent
hypothesis. In other words, if one of the three possible hypotheses
(i.e., positive, negative, null) is associated with more than 50% of
the available evidence score and the lower level of the 95% CI of
this proportion does not cross this decision rule value, one can
reasonably suppose this is the prevalent hypothesis in the scientific
literature.
The 95% CI of the score percentage (SP) can be calculated
according to the Agresti-Coull formula (which provides a
substantial improvement over the widely used Wald method
especially for proportion values near 0 and 1 and for small sample
sizes, as it can occur in the TTD):
Score percentage 95%CI~SPc+1:96   SE
where:
SPc~ ESiz 1:962=2
     
=TSc, that is the score percent-
age (SP) corrected according to the Agresti-Coull
method
SE~H SPc   1{SPc ðÞ ½  =TSc fg , that is the standard
error of SPc
TSc~
P
ESi ðÞ z 1:962   
, that is the total evidence
score (supporting any given hypothesis i) corrected
according to the Agresti-Coull method.
A formal comparison between a given score percentage (SP) and
the 50% (0.5) decision rule value can be made using a Z-test,
Targeted Therapy Database
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Z~ SP{0:5 ðÞ =SE
where:
SP~ESi=
P
ESi ðÞ
SE~H SPc   1{SPc ðÞ ½  =TSc fg
For a two-tailed test, the P-value is given by:
P{value~21 {W DZD ðÞ ½ 
where W (|Z|)=standard normal cumulative distribution.
Of course, the decision rule value (0.5) can be shifted up or
down to make it more or less stringent respectively, thus rendering
more or less conservative the conclusion regarding the relationship
between the patient’s profile and the response to treatment.
If none of the three hypotheses meets the decision rule, we can
reasonably suppose that there is no prevalent hypothesis, that is,
there is not enough evidence to link a given molecule (in a
particular state) to the efficacy/synergism/toxicity of a given drug.
5) Once we know that there is enough evidence to support the
hypothesis that no relationship exists between a molecule and a
drug, or that not enough evidence exists to support any hypothesis
on this relationship, this molecule is eliminated from the list of
molecules useful to predict drug responsiveness. Importantly, this
is not a definitive elimination, because new data will likely be
published on this relationship and thus the result of the summary
can change at any time. Since the TTD is routinely updated, the
selection of relevant molecules is a dynamic process that can
provide different results over time as the scientific knowledge
grows.
6) If the summary of evidence is instead in favor of the
hypothesis that a molecule (in a particular state) can modulate
Figure 3. A scheme of the evidence score method to synthesize the literature evidence and identify prevalent hypotheses
regarding the relationship of sensitivity/resistance between a given molecule (in a specific state) and a given drug. Each study is
assigned an evidence score based on the experimental model used to generate the findings reported in each article In this example, 70% of the total
score (that is, 70% of the published evidence rated according to the experimental model used to generate the findings reported in each article)
supports the hypothesis that molecule-X (in a particular state, here not specified for the sake of simplicity) is associated with responsiveness to drug-
Y. To be defined as ‘‘prevalent’’, the hypothesis must be characterized by the fact that the lower bound of the 95% confidence interval of its score
percentage does not cross the decision rule value (50%). The same method can be used to identify prevalent hypotheses regarding the relationship
of toxicity and synergism (see text for more details).
doi:10.1371/journal.pone.0011965.g003
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that molecule is added to the list of molecules potentially useful
(i.e., informative) to predict the responsiveness to the treatment.
To provide readers with a working example of the computations here described,
the above algorithm is fully implemented in the TTD spreadsheet entitled
‘‘Summary of Evidence’’ (available as an open-access file in the MMMP website).
Drug ranking system
Once a list of molecules for which ‘‘consistent’’ evidence is
available in favor of their role in predicting the responsiveness (or
refractoriness) to a specified therapeutic agent, as assessed by
means of the above described summary of the evidence, one might
be willing to test the relevant biospecimens from a given patient for
these molecules and match the patient’s molecular profile with the
currently available evidence on targeted therapy.
This opens the avenue to the use of the already available
scientific knowledge for generating hypothesis of personalized
treatment based on the fundamental principle of molecular
medicine: to use the patient (disease) molecular profile for
designing the treatment most effective and least toxic.
Before entering the technical details, one crucial issue must be
clearly addressed. The TTD has exclusively research purposes,
and thus neither the information nor the analytical models
included in this database should be used for the clinical decision
making process by any means. In fact, this way of summarizing the
evidence across (sometime very) different models has never been
reported before and thus it requires adequate validation before it
can be considered reliable on the clinical ground.
With this important caveat in mind, we propose to take the
following steps in order to match the patient’s molecular profile
with the current evidence on targeted therapy (see also Figure 4):
1) Using the above described score-based system, the
informative molecules (each along with a particular state of
expression/function) are extracted from the TTD along with their
score percentage (SP) and 95% CI. Each SP can be viewed as a measure
of strength of the hypothesis sustaining the relationship between the molecule and
the drug efficacy (toxicity, synergism) based on the available literature as rated
by the evidence score above described.
2) Score percentages (SP) of molecules associated with
sensitivity to treatment are initially assigned a ‘‘+’’ sign (e.g.
BRAF mutation V600E increases the efficacy of drug Sorafenib),
whereas molecules associated with resistance to treatment are
assigned a ‘‘2’’ sign (e.g. BRAF mutation V600E decreases the
efficacy of drug Sorafenib). Then, the concordance (or discor-
dance) between the molecular state of the prevalent hypothesis and
that of the patient (tumor) must be assessed. In particular, the sign
of the SP will be left unchanged if the patient carries the same
molecular state as that of the SP (e.g. BRAF mutation V600E); in
contrast, if the patient carries the ‘‘opposite’’ molecular state (e.g.
BRAF wild type), the SP will be assigned the opposite sign.
3) At this point, an overall score (OS) can be calculated as
the weighted average of the score percentage calculated for each
informative molecule. The OS and its confidence interval can be
calculated using the inverse variance method as follows:
OS~
X
Wi   SPi ðÞ =
X
Wi
And
Overall score 95%CI~OS+1:96   SE,
where:
SPi : score percentage of the prevalent hypothesis
calculated for each molecule (in a specific state) for
which the patient (cancer) has been tested
Wi=1/Vi, the weight assigned to each molecule based
on the variance of the SP
Vi=SPc * (12SPc), i.e. the variance of the SP calculated
for each molecule (see above)
SE=standard error=! (OV)
OV=overall variance=1/S Wi
The interpretation of the resulting score obviously depends
upon the decision rule one adopts. Using the 50% decision rule (as
we suggested for the summary of the evidence), two outcomes can
occur:
A) if the overall score for a given patient is greater than 50% (0.5)
and its95%CIdoes not cross the 50%decision rulevalue,one
can reasonably conclude that the available evidence supports
the hypothesis that this specific profile is associated with
sensitivity (or resistance, depending on the ‘‘direction’’ of the
overall score) to the treatment under evaluation;
B) if the overall score for a given patient either is lower than (or
equal to) 50% (0.5) or its 95% CI crosses the 50% decision
rule value, one can reasonably conclude that there is not
enough evidence linking this specific profile to the respon-
siveness (or refractoriness) to the treatment under evaluation.
A formal comparison between the calculated overall score (OS)
and the 50% (0.5) decision rule value can be made using a Z-test,
according to the following formula:
Z~ OS{0:5 ðÞ =SE
where OS and SE are defined as above reported. For a two-tailed
test, the P-value is given by:
P{value~21 {W DZD ðÞ ½ 
where W (|Z|)=standard normal cumulative distribution.
To provide readers with a working example of the computations here described,
the abovealgorithmis fully implementedin theTTDspreadsheetentitled ‘‘Profile
Matching’’ (available as an open-access file in the MMMP website).
Of course, the decision rule value (0.5) can be shifted up or
down to make it more or less stringent respectively, thus rendering
more or less conservative the conclusion regarding the relationship
between the patient’s profile and the response to treatment.
In this regard, we plan to validate the predictions of our model
by fitting logistic regression analysis to the scores generated by the
TTD. This is a standard approach for binary outcome prediction
models (responder vs. non-responder) and has several useful
features: 1) it allows to adjust for confounding factors (e.g., age,
gender, clinical setting, previous treatments) and even for the
creation of a multivariable prediction model using the logistic
regression linear predictor as a composite prediction score (which
would allow to synergistically exploit the predictive power of
multiple covariates); 2) predictive accuracy can be defined in terms
of discrimination and calibration by means of dedicated statistics
(e.g., Brier score and its decomposition); 3) Receiver Operating
Characteristic (ROC) curve analysis can help choose the optimal
score trade off value to define responders (currently set to 50%).
4) If the above procedure is performed for more than one
treatment (i.e., the patient’s molecular profile is matched with
Targeted Therapy Database
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drug rank based on the overall score obtained for each drug as
above outlined. A formal comparison between two overall scores
(e.g., OSa and OSb) relative to the matching of the patient’s profile
with drug A and drug B can be computed using a Z-test, according
to the following formula:
Z~ OSa{OSb ðÞ =SEa{b
where:
SEa{b~H OVazOVb ðÞ
OVa : variance of the overall score for the matching of
patient’s profile with drug A
OVb : variance of the overall score for the matching of
patient’s profile with drug B
For a two-tailed test, the P-value can be calculated using the
following formula:
Figure 4. A scheme of the drug ranking system to match the patient’s molecular profile with the available scientific evidence
regarding the relationship of sensitivity/resistance between a set of molecules (each in a specific state) and a given drug. After
identifying the prevalent hypothesis (along with its score percentage) for each molecule according to the evidence score method (see text and
Figure 3 for more details), the same molecules (and their state) are tested in the tumor of a patient. Each molecule is said to be concordant (positive
sign) or discordant (negative sign) according to whether the molecule state found in the patient’s tumor is identical or opposite to the state reported
in the literature, respectively. Then, a weighted mean of the score percentages is calculated to obtain the overall score for the patient. In this
example, the overall score indicates that on average 60% of the available evidence (that is, 60% of the published evidence rated according to the
experimental model used to generate the findings reported in each article) is in favor of the hypothesis that the patient’s molecular profile is
associated with responsiveness to drug-Y. To be defined as ‘‘sensitive’’ (or ‘‘resistant’’), a molecular profile must be characterized by an overall score
with a lower bound of its 95% confidence interval that does not cross the decision rule value (+50% or 250%, respectively). The same method can be
used to assess whether the available evidence supports the hypothesis that a molecular profile is associated with higher/lower toxicity for a given
drug-Y (see text for more details).
doi:10.1371/journal.pone.0011965.g004
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where W (|Z|)=standard normal cumulative distribution.
Of course, the same procedure can be used to match the
patient’s molecular profile with the available evidence regarding
drug/treatment toxicity.
Discussion
The Targeted Therapy Database is the first publicly available
repository that provides investigators with a searchable and
computation-compatible collection of the scientific evidence
regarding the targeted therapy of melanoma. Users can query
the database to easily obtain standardized information about the
molecular determinants of sensitivity or resistance of melanoma to
a given treatment, the compounds that can synergize with a given
treatment, as well as the molecular determinants of toxicity of a
given treatment.
This information can be utilized to quickly ascertain the most
studied as well as the emerging therapeutic strategies, along with
the models where they have been tested and the results yielded
so far.
Using the above presented model based on the evidence score,
these data can also be exploited to identify prevalent therapeutic
hypotheses, which is especially helpful when conflicting results are
reported in the literature. As above explained, although our model
cannot quantify the therapeutic benefit of a given targeted
therapy, it can be used to discern trends in the available evidence,
pinpointing the most promising approaches based on the amount
of literature (rated according to the scoring method described
above) in favor of each therapeutic hypothesis.
Finally, this archive - along with the algorithm we have
proposed - can be utilized to match the patient’s molecular profile
with the available literature and thus to hypothesize patient-
specific drug sensitivity toxicity or synergism based on the scientific
evidence supporting each type of relationship for each of the
molecules investigated.
We chose melanoma because this tumor paradigmatically
represents the urgency of providing patients with better treat-
ments: in fact, no current drug regimen significantly impacts on
the clinical course of this disease in the metastatic setting. Under
these unfortunate circumstances, any therapeutic choice based on
the available evidence (even without clinical proof of efficacy of
such a strategy) would appear more rational than offering patients
no options at all. However, since the drug ranking system
described above is based on a theoretical model, it should only be
used to generate hypotheses, not to make clinical decisions. In
other words, at the moment the findings obtained with our model
should only be used a posteriori (after the patients has been treated
with a regimen chosen independently of the model results) in order
to determine the actual performance of the model itself. Only this
validation of the model on the clinical ground will enable us to
verify whether our theoretical computations are accurate enough
to be clinically valuable, and thus to propose the implementation
of the model in the routine setting for choosing the therapeutic
regimen most likely to benefit individual patients.
Despite its intrinsic limitations (e.g., the score is arbitrary, the
literature coverage is incomplete and thus many hypothesis are
based on few or even single original articles), this model is - to the
best of our knowledge - the first attempt to directly apply the
enormous amount of data accumulated by the scientific commu-
nity in the field of personalized medicine. This translational
approach has the undeniable advantage of making the most of the
scientific production by using it comprehensively, without wasting
any evidence. This can be envisaged as an effort to deal with the
general problem that the biomedical community produces more
data than those utilized for clinical purposes. The actual
impossibility of testing each preclinical hypothesis in the clinical
setting represents undoubtedly a waste of potentially useful
information: this ‘‘abandoned’’ information could be ‘‘rescued’’
by taking it into consideration through the model we propose for
the evidence-based design of further research, both preclinical and
clinical. Should the clinical validation of this drug ranking system
demonstrate that it is reliable, the TTD could be utilized as a
template to develop similar repositories dedicated to any tumor
and more generally to any disease.
On the other hand, it should be clearly noted that scoring the
hypotheses reported in the literature as we propose to do here
cannot replace the standard rules of research, including clinical
phases of treatment evaluation and formal meta-analysis of
therapeutic interventions. The model we presented can only speed
up the identification of the most promising hypotheses of targeted
therapy by making an unprecedented comprehensive use of the
available evidence based on two principles: 1) any information is
potentially useful, independently of the experimental model that
has generated it, provided that different ‘‘weights’’ are assigned to
different models in order to reflect the difference in reliability; 2)
disease’s outcomes virtually always depend upon molecular
combinations, which calls for the simultaneous use of information
about all the molecules so far investigated, which should maximize
the likelihood of successfully drive targeted therapies.
As the available and eligible data are added to the TTD, we will
be able to make predictions more and more reliable because they
will be based on more information. In particular this will minimize
the risk of publication bias because some positive/significant
molecular associations published in the first place will be
‘‘balanced’’ by negative/non significant findings. We note that -
in analogy to standard meta-analysis - the greater the number of
studies considered the smaller the variance of the overall effect; in
our case, the smaller the sampling error the more accurate the
prediction. Furthermore, the growing information will enable
investigators to make setting specific predictions thanks to the
flexibility of the TTD: in fact, its format allows to insert more
columns (e.g., a new one could be dedicated to distinguish data
obtained in the primary tumor or metastatic setting) at any time.
Then our model can still be applied as above described because
the user can simply sort the database by the new column (e.g.,
primary vs. metastatic) and use only the relevant information (e.g.,
data from primary or metastatic setting) based on the clinical
question to be addressed.
Finally, we would like to underscore that this kind of project can
succeed only if the scientific community participates in the effort of
improving the model we have proposed. This can be realized in
several ways, such as: A) by giving notice of relevant articles not yet
included intheTTD,which will maximize theliterature coverage of
the database and thus will ultimately increase the reliability of the
analyses performed; B) by proposing new algorithms improving the
exploitation of the information contained in the database; C) most
importantly, by testing the hypotheses generated by the TTD
analyses both in the preclinical and clinical setting.
Overall, putting together the pieces of a ‘‘disease puzzle’’ is
becoming increasingly difficult due to the continuous and growing
flow of information that no single mind can keep up with: we
therefore propose the TTD (and the associated model for drug
ranking) as a tool for the synopsis and synthesis of the scientific
hypotheses with the aim of favoring the rational design of both
preclinical and clinical research.
Targeted Therapy Database
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researchers and clinical investigators taking care of the scientific
content of the MMMP website) is not only to keep the TTD
regularly updated but also to carefully take into consideration
suggestions, criticisms and contributions from the scientific
community.
We strongly believe that the bidirectional exchange of informa-
tion (from the database to the user and vice versa) represents the
most efficient way of gathering and exploiting scientific data on a
specific disease: in fact, if every researcher spent just a small amount
of time to share his/her knowledge to keep up-to-date the TTD or
any other similar project, the pace of discovery of more effective
anticancer strategies would be greatly increased.
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